(Q42694406)

English

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

scientific article published on 28 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 November 2017

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up (English)

1 reference

Europe PubMed Central

5 November 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

systemic lupus erythematosus

0 references

David A. Isenberg

9

1 reference

Europe PubMed Central

5 November 2017

Caroline Gordon

2

object named as

Caroline Gordon

1 reference

Europe PubMed Central

5 November 2017

Michelle A. Petri

5

object named as

Michelle Petri

1 reference

Europe PubMed Central

5 November 2017

8

object named as

Paul P Tak

1 reference

Europe PubMed Central

5 November 2017

3

object named as

Vibeke Strand

1 reference

Europe PubMed Central

5 November 2017

Kenneth C. Kalunian

6

object named as

Kenneth Kalunian

1 reference

Europe PubMed Central

5 November 2017

author name string

Daniel J Wallace

1

1 reference

Europe PubMed Central

5 November 2017

Kathryn Hobbs

4

1 reference

Europe PubMed Central

5 November 2017

Frederic Houssiau

7

1 reference

Europe PubMed Central

5 November 2017

Lexy Kelley

10

1 reference

Europe PubMed Central

5 November 2017

Brian Kilgallen

11

1 reference

Europe PubMed Central

5 November 2017

Anna N Barry

12

1 reference

Europe PubMed Central

5 November 2017

William A Wegener

13

1 reference

Europe PubMed Central

5 November 2017

David M Goldenberg

14

1 reference

Europe PubMed Central

5 November 2017

publication date

28 March 2013

1 reference

Europe PubMed Central

5 November 2017

1 reference

Europe PubMed Central

5 November 2017

52

1 reference

Europe PubMed Central

5 November 2017

7

1 reference

Europe PubMed Central

5 November 2017

1313-1322

1 reference

Europe PubMed Central

5 November 2017

Understanding the epidemiology and progression of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Lessons learned from clinical trials in SLE.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Why can't we find a new treatment for SLE?

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Review article: systemic lupus erythematosus: a review for anesthesiologists.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Measuring outcomes in systemic lupus erythematosus clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Advances in drug therapy for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Therapeutic targeting of B cells for rheumatic autoimmune diseases

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

B cells as therapeutic targets in SLE.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

CD22: an inhibitory enigma

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

From BILAG to BLIPS--disease activity assessment in lupus past, present and future

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKET129

21 January 2018

Identifiers

10.1093/RHEUMATOLOGY/KET129

1 reference

Europe PubMed Central

5 November 2017

1 reference

Europe PubMed Central

5 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42694406&oldid=1965650404"